Cell Derivation and Maintenance Core

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 1P01AI175399-01A1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2024
    2029
  • Known Financial Commitments (USD)

    $329,033
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    PROFESSOR Estelle Cormet-Boyaka
  • Research Location

    United States of America
  • Lead Research Institution

    OHIO STATE UNIVERSITY
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Post acute and long term health consequences

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

CORE 4 - SUMMARY COVID-19 remains a worldwide health threat. While some people recover quickly and have mild/no symptoms, at least one third develop long-term symptoms referred to as Long-COVID. In order to identify new therapeutic targets this Program will decipher the role of specific pathways and identify the cell-types that control inflammation and virus virulence. The "Cell Derivation and Maintenance Core" or Core 4 will support this Program by providing primary human and/or mouse airway epithelial cells, immune cells, endothelial cells, and cells isolated from the brain. This core will also provide blood as well as fixed brain and lung tissues from patients non-infected and infected with SARS-CoV-2. This core will support Projects 1-3 and will also provide primary airway cells to Core 3.